Chen Jianmin, Ali Fayaz, Khan Imran, Zhu Yi Zhun
School of Pharmacy and State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science & Technology Avenida Wai Long, Taipa, 999078, Macau.
State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science & Technology Avenida Wai Long, Taipa, 999078, Macau.
Curr Res Pharmacol Drug Discov. 2021;2:100057. doi: 10.1016/j.crphar.2021.100057. Epub 2021 Sep 14.
SARS-CoV-2, a newly emerged and highly pathogenic coronavirus, is identified as the causal agent of Coronavirus Disease (2019) (COVID-19) in the late December 2019, in China. The virus has rapidly spread nationwide and spilled over to the other countries around the globe, resulting in more than 120 million infections and 2.6 million deaths until the time of this review. Unfortunately, there are still no specific drugs available against this disease, and it is very necessary to call upon more scientists to work together to stop a further spread. Hence, the recent progress in the development of drugs may help scientific community quickly understand current research status and further develop new effective drugs. Herein, we summarize the cellular entry and replication process of this virus and discuss the recent development of potential viral based drugs that target bio-macromolecules in different stages of the viral life cycle, especially S protein, 3CL, PL, RdRp and helicase.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是一种新出现的高致病性冠状病毒，于2019年12月底在中国被确定为冠状病毒病（2019）（COVID-19）的病原体。该病毒已在全国迅速传播，并蔓延至全球其他国家，截至本综述撰写时，已导致超过1.2亿人感染和260万人死亡。不幸的是，目前仍没有针对这种疾病的特效药物，非常有必要呼吁更多科学家共同努力阻止疫情进一步蔓延。因此，近期药物研发的进展可能有助于科学界快速了解当前的研究状况，并进一步开发新的有效药物。在此，我们总结了该病毒的细胞进入和复制过程，并讨论了近期针对病毒生命周期不同阶段生物大分子的潜在病毒靶向药物的研发进展，特别是针对刺突蛋白（S蛋白）、3C样蛋白酶（3CL）、木瓜蛋白酶样蛋白酶（PL）、RNA依赖性RNA聚合酶（RdRp）和解旋酶的药物。
